New Delhi: Emcure Pharmaceuticals Ltd and its arm Gennova Biopharmaceutical have settled all legal disputes with HDT Bio Corp and signed a long-term agreement to develop mRNA vaccines, the company said on Thursday.
Under the agreement, the litigation between them, including the US court and the arbitral tribunal in London, has been resolved and dismissed, Emcure SAI said in a statement.
The parties have also entered into a long-term agreement to develop MRN vaccines against a wide range of infectious diseases in India and several other countries. As part of their agreement, HDT has granted Gennova a license to use its patented mRNA vaccine technology in several territories, I said.
"Genova and HDT, who previously collaborated on the successful development of Genova's mRNA COVID-19 vaccines, will once again collaborate on the development and commercialization of mRNA vaccines," the statement said.
Under the agreement, the litigation between them, including the US court and the arbitral tribunal in London, has been resolved and dismissed, Emcure SAI said in a statement.
The parties have also entered into a long-term agreement to develop MRN vaccines against a wide range of infectious diseases in India and several other countries. As part of their agreement, HDT has granted Gennova a license to use its patented mRNA vaccine technology in several territories, I said.
"Genova and HDT, who previously collaborated on the successful development of Genova's mRNA COVID-19 vaccines, will once again collaborate on the development and commercialization of mRNA vaccines," the statement said.
